FilingReader Intelligence
Conba Pharma's acetylcysteine solution approved by US FDA
March 27, 2025 at 08:52 PM UTC•By FilingReader AI
Zhejiang Conba Pharmaceutical (SSE:600572) announced that its wholly-owned subsidiary, Conba USA Inc., received FDA approval for its Abbreviated New Drug Application (ANDA) for acetylcysteine solution. The approved solution comes in 10% (100 mg/mL) and 20% (200 mg/mL) strengths. Acetylcysteine is used as a mucolytic agent for respiratory conditions and can also treat acetaminophen overdose.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600572•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Conba Pharmaceutical publishes news
Free account required • Unsubscribe anytime